Liposome Mitoxantrone

DRUG3 trials

Sponsors

BGI, China, Institute of Hematology & Blood Diseases Hospital, China

Conditions

AMLAcute Myeloid Leukemia (AML)Neoantigent(8;21)

Early Phase 1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling by invitationNCT06499025

BGI, ChinaAML, Neoantigen, t(8;21)

Start: 2024-02-01End: 2027-12-30Target: 16Updated: 2025-08-28

Phase 1

Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

Not yet recruitingNCT07828535

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Myeloid Leukemia (AML)

Start: 2026-10-30End: 2032-12-31Target: 30Updated: 2026-09-18

Phase 2

A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

Not yet recruitingNCT07754799

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Myeloid Leukemia (AML)

Start: 2026-09-30End: 2029-09-30Target: 320Updated: 2026-08-26

Related Papers

Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML

Blood2025-11-03